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Abstract: Solid core drug delivery systems (SCDDS) were prepared for the oral delivery of biomolecules
using mesoporous silica as core, bovine haemoglobin (bHb) as model drug and supercritical fluid (SCF)
processing as encapsulation technique. The use of organic solvents or harsh processing conditions
in the development of drug delivery systems for biomolecules can be detrimental for the structural
integrity of the molecule. Hence, the coating on protein-immobilised particles was performed via
supercritical carbon dioxide (scCO2) processing at a temperature lower than the melting point of
myristic acid (MA) to avoid any thermal degradation of bHb. The SCDDS were prepared by bHb
immobilisation on mesoporous silica followed by myristic acid (MA) coating at 43 ◦C and 100 bar in
scCO2. bHb-immobilised silica particles were also coated via solvent evaporation (SE) to compare the
protein release with scCO2 processed formulations. In both cases, MA coating provided required
enteric protection and restricted the bHb release for the first two hours in simulated gastric fluid
(SGF). The protein release was immediate upon the change of media to simulated intestinal fluid
(SIF), reaching 70% within three hours. The release from SCF processed samples was slower than SE
formulations, indicating superior surface coverage of MA on particles in comparison to the SE method.
Most importantly, the protein conformation remained unchanged after the release from SCDDS as
confirmed by circular dichroism. This study clearly demonstrates that the approach involving protein
immobilisation on silica and scCO2 assisted melt-coating method can protect biomolecules from
gastric environment and provide the required release of a biologic in intestine without any untoward
effects on protein conformation during processing or after release.
Keywords: biomolecules; oral delivery; supercritical CO2; myristic acid; haemoglobin
1. Introduction
Parenteral administration is the most common route for therapeutic peptide/protein delivery [1].
However, the short half-life of biologics due to their sensitive nature and chronic therapy requirements
in majority of treatments make repetitive dosing unavoidable. Injectables, the most common route
of delivery, also require formulation improvements. Current developments in invasive delivery of
biomolecules include formulations based on encapsulation of protein into lipid based microparticles
and a polymeric matrix to control the release and achieve a prolonged effect [2]. Since the matrix
remains in the body for a considerable period, materials used to formulate them must have non-toxic
degradation products. Polyesters, polyanhydrides, and naturally occurring materials, including gelatin,
alginate and chitosan, are amongst the most commonly used polymers to develop sustained release
protein formulations [3]. However, most of these still fail to answer issues related to cost, frequent
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injections and low patient compliance. Hence, finding alternatives to parenteral delivery is highly
important as the application of biologics as therapeutics increases. Therefore, research in non-invasive
administration of biomolecules is required. The development of drug delivery systems for biologics
is a complex process and cannot be compared to small molecules due to the size and sensitivity of
these molecules [4]. There are very few peptides/proteins that are administered through a route other
than parenteral. Examples of marketed non-parenteral protein formulations include Fortical® (nasal
calcitonin spray) for the treatment of post-menopausal osteoporosis and Oralyn® (buccal insulin
formulation) for terminally ill patients. Alternatives to parenteral delivery are challenging due to issues
related to other potential routes. For example, protein denaturation due to stomach acid, enzymatic
degradation, mucocilliary clearance and impermeability across the intestinal wall are well known
issues associated with oral delivery. Another major challenge in developing novel drug delivery
systems for biologics is linked to exposure of biomolecules to harsh processing conditions such as
high shear stress, temperature and organic-water solvent interface, which may lead to structural
changes in proteins [5]. For example, encapsulation can be achieved by a wide range of processes,
such as spray-drying, solvent evaporation, extrusion, coacervation, etc. However, these processes
require the use of organic solvents and subject the drug to high stress and/or temperature. Therefore,
processing materials that are sensitive to these conditions, e.g., proteins and peptides, is challenging
via conventional techniques.
Supercritical fluid technology (SCFT) can provide a solution to the problems associated with
conventional encapsulation methods. The advantages of SCFT include avoiding the use of organic
solvent, operation at low temperatures, and the ability to work in oxygen- and water-free environment
to prevent thermal, oxidative and solvent-induced degradation of a material [6]. scCO2 is the most
commonly employed solvent for the particle engineering and encapsulation purposes as it allows
processing at comparatively low pressures (critical pressure: 72.8 bar) and temperatures (critical
temperature: 31.1 ◦C) and it is chemically inert, easily available, environmentally benign and easy to
remove [7].
Most protein drug delivery systems are based on biodegradable polymeric nanoparticles, liposomes
and dendrimers [8]. A controlled release is obtained from these materials upon structural degradation
of the carrier triggered by various chemical factors, such as pH and temperature. However, premature
release of drugs still remains an issue with these systems. The use of inorganic material has been
also investigated by many to overcome the problem of premature release and to provide a sustained
delivery. Among the many stable biocompatible excipients, silica is generally the material of choice
and has been studied in many drug delivery systems [9,10]. Properties such as biocompatibility,
hydrophilicity and protection to internal payload make mesoporous (pore size 2–50 nm) silica particles
a perfect candidate for drug delivery. Moreover, the release rate can also be controlled by tailoring the
size and shape of these particles [11]. Another important advantage of silica is the ease of its surface
modification to optimise the drug loading and release kinetics [12]. Silica is also considered to have
better a biocompatibility in comparison with other metal oxides such as titanium and iron oxide [13].
Artificial implants of silica and its composites are known to have osteogenic properties and it is very
well established that silica is able to store and gradually release drugs like antibiotics and other small
molecules [9,13]. Moreover, it is also known that the biocompatibility of several drug delivery systems
such as biopolymers, micelles and magnetic nanoparticles can be enhanced by the use of silica [13–15].
Hence, silica can be an excellent carrier for biomolecules and that is why it is used as a core material
for protein immobilisation in the present study.
Myristic acid (MA) is a saturated fatty acid with a long hydrocarbon side chain and carboxyl
group. It is a generally regarded as a safe (GRAS) material and has found numerous applications
in pharmaceutical and food industry as it is easily available, biologically inert, nontoxic and
biocompatible [16]. Saturated long chain fatty acids are commonly used in various pharmaceutical
applications and are frequently studied in the development of drug delivery systems. Examples of the
fatty acids in drug delivery include implants containing insulin, ofloxacin-loaded palmitic acid solid
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lipid nanoparticles, stearic acid nanoparticles loaded with cyclosporine A, encapsulation of paclitaxel
into lauric acid based micelles and cefuroxime-axetil containing stearic acid microparticles [17–21].
Similarly, MA coating of chitosan salts containing vancomycin hydrochloride provided the required
enteric properties to obtain colon-targeted drug release [22]. The favourable physico–chemical
characteristics of MA related to its enhanced solubility at alkaline pH due to the ionisation of the
carboxylic acid group in comparison to acidic pH can be utilised in developing formulations with
essential enteric properties.
The rationale behind SCDDS is very simple and involves immobilisation of a biologic on
mesoporous particles to reduce molecular flexibility and improve the stability against pH, temperature
and enzymatic degradation [23,24]. The second step involves coating of MA without exposing
biomolecules to harsh conditions, via scCO2 processing to obtain second layer of protection and the
desired release in the required environment. The aim of this study was to formulate SCDDS for the
oral delivery of biologics with required enteric properties to ensure safe passage of biomolecules to
thr upper intestine using bHb as a model drug, silica as the core material and scCO2 as the media to
obtain MA coating. The rationale behind this work was to find a cost-effective drug delivery system
with required enteric properties for biomolecules.
2. Results and Discussion
2.1. Maximum bHb Adsorption and Adsorption Kinetics
It is known that proteins contain a net positive charge below their isoelectric point (pI) and have
an overall negative charge above it. The rate of protein adsorption is likely to be high when the
adsorbent surface and protein bear opposite charges. This higher rate of adsorption in these conditions
is primarily driven by the electrostatic attractions which accelerates the protein migration towards
the oppositely charged surface [25]. The adsorption studies presented in this study were performed
in pH 6 phosphate buffer (0.133 M) due to the overall positive charge on bHb, considering the pI
of bHb to be 7.1 [26] and a negative charge on silica particles such that the ionic interactions could
be encouraged. Another reason for the selection of this pH was the higher protein stability at pH 6
compared to pH 7 and 8 under stirring at room temperature [27,28]. The bHb adsorption on silica
(Figure 1) increased linearly with the increase in protein concentration, reaching a plateau at 12 mg/mL
(225 mg/g) with only a slight increase in protein immobilisation at 15 mg/mL (236 mg/g).
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The data for bHb adsorption on silica particles was fitted with both Langmuir and Freundlich
models, resulting in R2 values of 0.7915 and 0.9864, respectively. The Freundlich-type adsorption of
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bHb on SFP indicated that it is a multi-layer process in which the amount of adsorbed solute per unit
adsorbent mass increases gradually with the increase in bHb concentration [29].
The adsorption kinetics of bHb adsorption on SFP presented in Figure 2 indicate the high affinity
of protein to silica particles.
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the adsorbate concentration in the media and its propensity to migrate to the adsorbent surface [30].
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The complete nitrogen adsorption and desorption isotherm for SFP presented in Figure 4 resembled
the BDDT Type IV, indicative of the mesoporous nature of the particles. The hysteresis in this
isotherm resembled Type H1, meaning that these particles consisted of agglomerates or compacts of
approximately uniform spheres in a regular array [34]. BET isotherm of bHb-adsorbed silica retained
its Type IV nature but showed a decrease in specific surface area. The BET surface area of SFP decreased
from 307 m2/g to 226 m2/g after bHb adsorption.
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inside the pores or the blockage of pore openings by protein molecules after the adsorption process.
Similarly, an increase in the point of zero charge (PZC) for silica from pH 1.6 for bare particles to 6.7 for
protein immobilized particles (closer to the IEP of bHb) also indicated coverage of particle surface with
bHb molecules.
2.3. SCDDS Preparation
The preparation of SCDDS involved protein immobilisation on a solid surface followed by coating
to control the drug release. The protein immobilisation on a solid surface is known to reduce the
molecular flexibility, leading to enhanced stability [22]. Moreover, coating thereafter ensures that
these particles have optimal enteric properties to protect the protein from gastric pH and control the
release [36]. The SCDDS formulation process can be summarised as follows:
As illustrated in Figure 6, the first step in this process allows the bHb molecules from the aqueous
solution to be adsorbed on the silica surface which is then collected via centrifugation and dried to
obtain bHb-immobilised SFP particles. The protein adsorbed particles are then coated with MA via
melt-deposition method in scCO2 to limit possible denaturation due to oxidation, hydrolysis and
solvent, stress and temperature-induced degradation. The rationale behind using MA coating is also to
protect the protein from gastric media due to its limited solubility in acidic conditions and to promote
drug release in intestinal environment.
Pharmaceuticals 2019, 12, x FOR PEER REVIEW 6 of 15 
Similarly, an increase in the point of zero charge (PZC) for silica from pH 1.6 for bare particles to 6.7 
for protein immobilized particles (closer to the IEP of bHb) also indicated coverage of particle surface 
with bHb molecules.  
2.3. SCDDS Preparation 
The preparation of SCDDS involved protein immobilisation on a solid surface followed by 
coating to control the drug release. The protein immobilisation on a solid surface is known to reduce 
the molecular flexibility, leading to enhanced stability [22]. Moreover, coating thereafter ensures that 
these particles have optimal enteric properties to protect the protein from gastric pH and control the 
release [36]. The SCDDS formulation process can be summarised as follows: 
 
Figure 6. Schematic diagram of solid core drug delivery system (SCDDS) preparation. 
As illustrated in Figure 6, the first step in this process allows the bHb molecules from the 
aqueous solution to be adsorbed on the silica surface which is then collected via centrifugation and 
dried to obtain bHb-immobilised SFP particles. The protein adsorbed particles are then coated with 
MA via melt-deposition method in scCO2 to limit possible denaturation due to oxidation, hydrolysis 
and solvent, stress and temperature-induced degradation. The rationale behind using MA coating is 
also to protect the protein from gastric media due to its limited solubility in acidic conditions and to 
promote drug release in intestinal environment. 
SFP, SFP-bHb and SCDDS were analysed using ATR-FTIR to confirm protein adsorption, coating 
and whether bHb went through any conformational changes due to immobilisation at the given 
conditions. The spectra presented in Figure 7 show amid I and amid II peaks at 1644 and 1530 cm-1, 
respectively. 
Figure 6. Schematic diagram of solid core drug delivery system (SCDDS) preparation.
SFP, SFP-bHb and SCDDS were analysed using ATR-FTIR to confirm protein adsorption, coating and
whether bHb went through any conformational changes due to immobilisation at the given conditions.
The spectra presented in Figure 7 show amid I and amid II peaks at 1644 and 1530 cm−1, respectively.
Amide I and amide II bands are two major bands of the protein infrared spectrum [37]. The amide
I band (between 1600 and 1700 cm−1) is directly related to the backbone conformation and it is mainly
associated with the C=O stretching vibration. The N-H bending vibration and the C-N stretching
vibration results in amide II between 1450 and 1550 cm−1. This amide II band is conformationally
sensitive and can provide information about protein folding/unfolding. Both peaks are still present in
bHb immobilised SFP with reduced peak intensity but without any shift, confirming the lack of changes
to protein conformation due to immobilisation. The absence of characteristic peaks (amide I and II) of
protein and the emergence of the peak for carboxyl groups at 1701 cm−1 along with the reduction in
the intensity of siloxane (Si-O-Si) band at 1055 cm−1 demonstrate MA coating of the silica surface.
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2.4. In-Vitro Release Studies at pH 1.2 and 6.8
One of the major issues with protein immobilisation on mesoporous surfaces is the inability to
obtain sufficient desorption thereafter due to the increase in the surface free energy. Hence, addition of
a displacer in the dissolution media was explored to enhance the protein release from these systems.
Alth ugh protein desorption can be obtained via changes in solvent ionic strength, pH and/or use of
surfactants, it is important t carefully consider the choice of the displacement mechanism to ensure
conformational integrity [38–42]. Pluronics are triblock polymers consisting of polyethylene and
olypropylene blocks and act as non-ionic surfactants. Prior t release studies, experiments were
performed to determine the efficiency of pluronic F127 (F127) as protein isplacer and its impact on
t e protein conformation. Figure 8 shows the effect of F217 concentration on the protein desorption
from silica surface.
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Figure 8. bHb desorption from SFP particles in pH 6.8 phosphate buffer at 37.4 ◦C using F-127 as
a displacer.
The increase in F127 concentration in the media resulted in higher protein release of up to 1 mg/mL
with no real change to the release profile with the further increase of F127 to 5 mg/mL. The effect of F127
in the media on protein conformation was evaluated using CD spectroscopy, which showed no impact
on the secondary structures of the bHb, as presented in Figure 9, in terms of the percentage content of five
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different secondary structures. These were calculated using CDNN software developed by Dr. Gerald
Böhm (Institut für Biotechnologie, Martin-Luther Universität Halle-Wittenberg), which deconvolutes
the CD data by cross-referencing the sample spectrum with already installed reference spectra [28].
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Figure 10. Release of bHb from MA coated SFP based SCDDS prepared with both SCF and SE methods 
in SGF (pH 1.2) and SIF (pH 6.8) at 37.4 °C. 
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These findings were similar to the results from Pettit et al. in which systems prepared by solvent
coating of MA showed release of adsorbed protein only at alkaline pH and Cerchiara et al. also showed
that FA coating imparted enteric properties to vancomycin loaded chitosan particles prepared by freeze
drying [22,36]. bHb release upon exposure to SIF was immediate, which may be related to the solubility
behaviour of MA. The solubility of MA increases at a higher pH, which can subsequently facilitate the
continuous erosion of coating and higher protein release at the studied conditions [45]. bHb release
in SIF was the highest (71%) from SFP:MA0.5-PEN, followed by SFP:MA0.5-SCF, SFP:MA1.0-PEN,
and SFP:MA1.0-SCF with a release of 62%, 56% and 48%, respectively.
Although SE coating imparted the required enteric properties to the formulation, SCDDS prepared
by SCF processing showed a comparatively lower and slower release in comparison to particles coated
by SE. This could be due to the better coating and improved surface coverage of MA when SCF-assisted
melt-coating was used in comparison to SE. The protein release was also dependent on the MA/silica
ratios, where 0.5:1 showed a higher release compared to 1:1 for SCDDS prepared using both coating
methods. For instance, SFP:MA0.5-SCF released a total of 62% bHb, which was 14% higher than
the formulation containing a 1:1 (MA:silica) ratio. Similarly, the total release from SCDDS prepared
by solvent evaporation was 56% (1:1) and 71% (0.5:1). The increase in FA ratio in the formulation
resulted in a decreased bHb release, which is expected to have been due to the slow erosion of the
MA layer above the solubility limit. Moreover, SCF processing of MA also allowed the coating to
have been performed at 43 ◦C rather than its actual melting point of 54.5 ◦C, which occurred due
to the dissolution of CO2 in a myristic acid crystalline matrix. This also ensured that bHb was not
exposed to comparatively higher temperature which would be the case if melt-coating was performed
at atmospheric pressure.
The dissimilarity (F1) and similarity (F2) factors were calculated to determine whether there were
any statistical differences (Table 1) between the bHb release from coated and uncoated particles.
Table 1. F1 and F2 calculations for the release of bHb from uncoated and SCDDS particles.
Time (min)
% Mean bHb Released ± S.D
Control SFP:MA0.5-SCF SFP:MA1.0-SCF SFP:MA0.5-PEN SFP:MA1.0-SCF
135 74.3 ± 1.1 48.2 ± 3.7 31.6 ± 2.5 55.2 ± 4.2 45.3 ± 5.0
180 85.4 ± 1.2 53.3 ± 2.6 42.2 ± 2.0 65.4 ± 3.8 52.8 ± 3.5
240 89.2 ± 1.0 59.7 ± 3.2 45.2 ± 1.5 71.3 ± 4.3 53.9 ± 4.1
360 89.2 ± 2.0 59.2 ± 4.1 46.2 ± 2.8 71.9 ± 4.8 55.5 ± 4.7
F1 35 51 22 39
F2 27 18 36 24
The F1 should be between 0 and 15, whereas F2 should be between 50 and 100 for two dissolution
profiles to be considered similar [46]. For all the above formulations, F1 was higher than 15 and F2 was
lower than 50. Hence, it can be concluded that the release from formulations was dissimilar to the
control in every scenario.
Improper design or formulation of biologics can result in degradation, denaturation, and/or
aggregation of the protein molecules, potentially causing both immunogenic side effects after
administration and loss of pharmacological activity. Hence, the conformation of the released bHb was
determined to understand whether the immobilisation, coating or release caused any changes to the
protein’s secondary structure.
The CD spectra of the untreated and released protein from SCDDS prepared via SCF and SE
methods are presented in Figure 11. The CD spectrum of the released protein shows similar maxima
and minima to untreated bHb, indicating that it largely retained its confirmation after release [47].
The obtained CD spectra were processed by the CDNN software to determine the fraction content of
different secondary structures of the protein. The percentage content of secondary structures from CD
spectra for protein released from MA coated formulations is shown in Table 2.
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Table 2. Percentage content of secondary structures [mean ± SE (n = 2)] of untreated bHb and bHb
released from MA-coated SFP formulations.
Secondary Structure bHb (Untreated)
bHb Released from SFP Formulation
SCF Coated Pentane Coated
Helix 60.5 ± 1.5% 59.1 ± 0.4% 60.7 ± 0.9%
Antiparallel 0.7 ± 0.1% 0.8 ± 0.0% 0.7 ± 0.1%
Parallel 4.9 ± 0.2% 5.1 ± 0.1% 4.9 ± 0.2%
Beta turns 12.4 ± 0.2% 12.5 ± 0.1% 12.3 ± 0.1%
Random coil 20.7 ± 1.0% 21.2 ± 0.1% 20.6 ± 0.7%
The α-helix content of the protein released from formulations was the same as the freshly prepared
bHb solution, i.e., approximately 60%. Similarly, the rest of the secondary structures content was also
comparable to the untreated sample, confirming the absence of any conformational changes in the bHb
molecules either due to processing or exposure to the release media.
3. Materials and Methods
3.1. Materials
Bovine haemoglobin, >95% (bHb), myristic acid, ≥99% (MA), Pluronic F-127, (BioReagent
grade) sodium hydrogen phosphate (≥99%), potassium dihydrogen phosphate (≥98%), hydrochloric
acid (37% v/v), sodium hydroxide (≥97%) and pentane (98%) were purchased from Sigma Aldrich
(Gillingham, UK). Syloid 244 FP silica particles (SFP) were kindly donated from Grace Davison (Lokeren,
Belgium). Liquid CO2 with the purity of 99.9% was supplied by BOC ltd (Rochester, UK). All chemicals
were used as received without any further purification.
3.2. bHb Adsorption and Kinetics
The maximum protein immobilisation on silica particles was determined using 0.5, 1, 2, 4, 8, 12,
15 mg/mL protein solutions in pH 6 phosphate buffer. The adsorption study was performed using
400 mg of silica suspended in 10 mL solution of each concentration. The contents were stirred at
250 rpm at room temperature and the supernatant was collected, filtered using a 0.45-µm syringe filter
and analysed by UV spectrophotometer (UV-2550, Shimadzu, Kyoto, Japan) after 4 h. The kinetic
measurements were conducted using 8 mg/mL protein solution in pH 6 phosphate buffer. Similar
to maximum bHb adsorption study, 400 mg of silica was suspended in 10 mL of protein solution.
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The contents were stirred at 250 rpm and UV measurements were taken after 15, 30, 45, 60, 90, 120, 180,
240 and 300 min at 285 nm. The quantity of bHb adsorbed was calculated using an indirect method,
i.e., by subtracting the remaining amount of bHb in the supernatant from the initial content. The
experiments were conducted in triplicate and at ambient conditions.
3.3. Coating of Silica Particles by SCF Processing
The protein-adsorbed particles were separated from the media via centrifugation at 3700 rpm
(Centrifuge 5430, Eppendorf, Stevenage, UK) for 10 min and freeze-dried at −55 ◦C under deep vacuum
using a ScanVac CoolSafe freeze dryer (LaboGene ApS, Lillerød, Denmark). The dried particles were
coated by SCF processing with MA at a temperature and pressure reported elsewhere (43 ◦C and
100 bar) [27,48]. The instrumental set up is detailed in Figure 12, which consists of a temperature-
controlled 150 mL and 3.5-cm-thick stainless steel cylinder with sapphire windows to monitor
the experiments.
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Figure 12. Sche ati t ti of supercritical fluid (SCF) instrument [CO2 cylinder (A), chiller (B),
CO2 pump (C), hig pressure v ss l (RV), automatic back pressure regulator (ABPR), controller (D)
and display unit (E)].
The interior of the vessel was illuminated by a light source (L) which allowed the process to be
monitored live using a camera (K) directly attached to the vessel via sapphire window. An ABPR was
used to control the pressure inside the vessel and to obtain controlled depressurisation. The desired
pressure and temperature values were assigned and monitored from the control unit (D). The rate
of CO2 addition and evacuation along with the live feed from the camera was monitored on the
computer (E).
The ratios of protein-immobilised-silica to MA (w/w) used were 1:0.5 and 1:1. For coating, the required
weights of protein-immobilised-silica and MA at desired ratios were introduced into the preheated
(43 ◦C) high-pressure vessel. The vessel was then closed and liquid CO2 was pumped at a rate of
10 g/min until the pressure of 100 bar was achieved. The system was then left to equilibrate under
stirring at 250 rpm for 10 min. The mixture in the vessel was stirred for another 15 min and then
depressurised at a rate of 8 bar/minute to collect coated particles. The particles were collected, gently
homogenised, sieved through a 100 µm sieve and stored at 5 ◦C until required for analysis and
drug release.
Pharmaceuticals 2019, 12, 153 12 of 15
3.4. Coating of Silica Particles by Solvent Evaporation
The protein immobilised SFP particles were also coated by SE method as described by Pettit et al.
to compare the efficacy of SCF coating [36]. The required amount of MA was dissolved in 15 mL of
pentane and the bHb immobilised particles were suspended in it. The suspension was left to stir at
250 rpm in a fume hood at room temperature until the solvent was completely evaporated. Similarly
to above, particles were collected, gently homogenised, sieved through a 100 µm sieve and stored at
5 ◦C until required for analysis and drug release.
3.5. Analysis
3.5.1. bHb Quantification
A UV-Vis (UV-2550, Shimadzu, Kyoto, Japan) analysis was used for the quantification of bHb
using a matched pair of quartz cuvette with a path length of 1 cm. The samples were always filtered
through 0.45 µm filters before obtaining the spectrum between 200 to 700 nm. The concentrations were
calculated using a calibration curve of bHb at 285 nm.
3.5.2. Conformational Integrity Determination
The conformational integrity of bHb after release from SCDDS was determined using circular
dichroism (Chirascan qCD; Applied Photophysics, Leatherhead, U.K.). The CD spectrum was recorded
using 1 mm pathlength cylindrical quartz cuvette in the far UV region between 190 to 260 nm with a
bandwidth of 1 nm and sampling time of 2 s per point. The CD spectra obtained were then deconvoluted
using CDNN software supplied by Applied Photophysics to obtain the fractional content of the five
secondary structures.
3.5.3. Nitrogen (N2) Sorption Analysis
A BET analysis was performed using Gemini 2380 (Micromeritics instrument corporation, Hexton,
U.K.) on SFP and bHb immobilised SFP particles. An amount of 10–15 mg of particles were weighed
in the sample tube and degassed with nitrogen in order to remove any moisture or adsorbed gases.
The degas conditions used for pure and protein adsorbed silica were 100 ◦C for 4 h and 40 ◦C for 8 h,
respectively. Sample and reference tubes were then placed firmly inside the instrument and were
dipped in liquid nitrogen. The air in the tubes was evacuated at a rate of 50–100 mmHg/min for 5 min.
Complete BET adsorption and desorption isotherms were obtained at P/P0 from 0.05 to 1. Pore sizes
were calculated using the BJH model.
3.5.4. ATR-FTIR Analysis
The infrared spectra of SFP, bHb adsorbed SFP and SCDDS particles were obtained using a
Spectrum Two ATR-FTIR spectrometer (Perkin Elmer, Beaconsfield, UK). Approximately 1 to 2 mg of
the particles was spread uniformly on the surface of a single reflection horizontal ATR accessory with a
zinc selenide (ZnSe) crystal and adequate pressure was exerted on the sample using the pressure-arm.
The spectra were collected from 4000–400 cm-1 range in transmission mode. Approximately 16 scans
were collected for each spectrum with a spectrum resolution of 8 cm−1.
3.6. In-vitro Release Studies in Simulated Gastric (SGF) and Intestine (SIF) Fluids
In-vitro bHb release from SCDDS was performed in SGF and SIF without enzymes were prepared
according to USP [49]. The media also contained 0.1% w/v (1 mg/mL) pluronic F-127 as a displacer to
ensure that optimal release could be obtained from these formulations. SGF was prepared using 0.1 M
HCl (pH 1.2) and SIF was obtained by mixing 25 mL of 0.2 M monobasic potassium phosphate with
11.2 mL of 0.2 M sodium hydroxide solutions, made up to 100 mL with de-ionised water. An amount
of 100 mg of SCDDS was suspended in 100 mL of the dissolution media and continually stirred at
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100 rpm during the release studies. The readings were recorded after 15, 60 and 120 min in SGF
before switching to SIF to obtain the release at 135, 180, 240, 360 and 1440 min. An amount of 5 mL
of sample was withdrawn at the abovementioned intervals and filtered using 0.45 µm syringe filter
before determining the UV absorbance at 285 nm. The volume of the release media was kept constant
by the addition of 5 mL of the fresh media after every sample withdrawal. The experiments were
performed at 37.4 ± 0.2 ◦C and in triplicate.
4. Conclusions
SCDDS for the oral delivery of biomolecules was prepared by the bHb immobilisation on
mesoporous silica followed by coating of myristic acid via scCO2-assisted melt coating and conventional
solvent evaporation methods. The advantage of using scCO2 processing was to obtain the coating at
a lower temperature than the melting point of MA at atmospheric pressure and to avoid the use of
an organic solvent. The in-vitro bHb release from myristic acid coated SFP based SCDDS in intestinal
fluid resulted in 45%–70% protein release depending on the myristic acid ratio and coating method.
CD analysis on the protein released from SCDDS did not show any changes in the secondary structures,
which proves that SCF processing at studied conditions had no effect on the conformation of bHb.
This study showed that mesoporous silica and myristic acid can be used as core and shell materials to
develop SCDDS for large therapeutic molecules to obtain pH-dependent release without causing any
protein denaturation.
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